NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis $7.61 -0.32 (-4.04%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$7.80 +0.19 (+2.50%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Day One Biopharmaceuticals Stock (NASDAQ:DAWN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DAWN alerts:Sign Up Key Stats Today's Range$7.52▼$7.9350-Day Range$7.61▼$13.2152-Week Range$7.52▼$18.07Volume1.03 million shsAverage Volume1.10 million shsMarket Capitalization$771.31 millionP/E RatioN/ADividend YieldN/APrice Target$32.29Consensus RatingBuy Company OverviewDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Read More… Remove Ads Day One Biopharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreDAWN MarketRank™: Day One Biopharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 450th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDay One Biopharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Day One Biopharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to decrease in the coming year, from ($0.72) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -7.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -7.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Day One Biopharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.91% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 6.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted22.91% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 6.38%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.41 News SentimentDay One Biopharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Day One Biopharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for DAWN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $251,925.00 in company stock.Percentage Held by InsidersOnly 8.40% of the stock of Day One Biopharmaceuticals is held by insiders.Percentage Held by Institutions87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Day One Biopharmaceuticals' insider trading history. Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Stock News HeadlinesThe Goldman Sachs Group Has Lowered Expectations for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock PriceMarch 27, 2025 | americanbankingnews.comDay One Biopharmaceuticals price target lowered to $34 from $39 at JPMorganMarch 5, 2025 | markets.businessinsider.comTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.April 2, 2025 | Crypto 101 Media (Ad)Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case TheoryMarch 5, 2025 | msn.comOppenheimer Sticks to Their Hold Rating for Day One Biopharmaceuticals (DAWN)February 27, 2025 | markets.businessinsider.comDay One price target lowered to $30 from $34 at JonesResearchFebruary 27, 2025 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Day One Biopharmaceuticals (DAWN)February 26, 2025 | markets.businessinsider.comDay One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comSee More Headlines DAWN Stock Analysis - Frequently Asked Questions How have DAWN shares performed this year? Day One Biopharmaceuticals' stock was trading at $12.67 at the start of the year. Since then, DAWN stock has decreased by 39.9% and is now trading at $7.61. View the best growth stocks for 2025 here. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) released its earnings results on Tuesday, February, 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.34. The business had revenue of $29.21 million for the quarter, compared to analyst estimates of $27.11 million. When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $126 million in an IPO on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Day One Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Day One Biopharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Tesla (TSLA). Company Calendar Last Earnings2/25/2025Today4/01/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DAWN CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$32.29 High Stock Price Target$40.00 Low Stock Price Target$25.00 Potential Upside/Downside+324.3%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-188,920,000.00 Net MarginsN/A Pretax Margin-82.02% Return on Equity-22.40% Return on Assets-19.79% Debt Debt-to-Equity RatioN/A Current Ratio14.62 Quick Ratio14.55 Sales & Book Value Annual Sales$131.16 million Price / Sales5.88 Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book1.91Miscellaneous Outstanding Shares101,355,000Free Float92,375,000Market Cap$771.31 million OptionableOptionable Beta-1.38 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:DAWN) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.